Overall, 43% of patients presented severe thrombocytopenia (<50,000 platelets/μL), 40% hepatic dysfunction (total bilirubin >3.0 mg/dL or AST or ALT >120 U/L), and 34% severe anaemia (Hb <7.0 g/dL). Here, GSTM1 is linked to anemia (phenotype).